The Health Resources and Services Administration last week warned pharmaceutical companies that they must continue to offer 340B Drug Pricing Program discounts on some uses of orphan drugs.
Caris Life Sciences Inc. last week reduced its workforce by 50 people—about 20 percent, sources said.
The Cancer Letter asked Lawrence Einhorn, distinguished professor of medicine and the Livestrong Foundation Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, to reflect on one of the most spectacular successes in the history of cancer research—his development of the curative regimen for testicular cancer.
On Oct. 21, 1974, John Cleland lay in a hospital bed at Indiana University Hospital.
The fourth edition of the European Code Against Cancer was published by the International Agency for Research on Cancer, with the participation of the European Commission.
The American Society of Clinical Oncology endorsed a joint clinical practice guideline on molecular testing published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Cancer centers and other hospitals, reeling from the loss of discounts and rebates on three widely used cancer drugs, are seeking to persuade drug maker Genentech to reverse its decision to channel these medications through six specialty distributors.
The Cancer Letter asked Patrick Loehrer, director of the Indiana University Melvin & Bren Simon Cancer Center, to discuss his institution's decision to close its 10-year-old proton beam center.
At its opening a decade ago, the Indiana University Health Proton Therapy Center was one of four such facilities in the U.S.
